Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncology. 2011;80(1-2):63-9. doi: 10.1159/000328281. Epub 2011 Jun 9.

Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.

Author information

1
Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. hnagano@gesurg.med.osaka-u.ac.jp

Abstract

BACKGROUND/AIM:

We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than twice the number of patients relative to the previous report; it also evaluates the clinical predictor on the response to the combination therapy and long-term survival.

METHODS:

The study subjects were 102 patients with advanced HCC and tumor thrombi in the major branches of the portal vein (Vp3 or 4). They were treated with at least 2 courses of IFN-α/5-FU.

RESULTS:

No major treatment-related complications were noted. In the 102 patients, 40 (39.2%) showed objective response [11 (10.8%) showed complete response, 29 (28.4%) partial response], 8 (7.9%) showed no response and 54 (52.9%) showed progressive disease.

CONCLUSION:

IFN-α/5-FU combination therapy is a promising modality for advanced HCC with tumor thrombi in the major portal branches.

PMID:
21659784
DOI:
10.1159/000328281
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center